Image Source: Zacks Investment Research We note that PacBio had reported a wider year-over-year adjusted loss of 34 cents per share for the second quarter of 2022 although revenues were up almost 16%. On the second-quarterearnings call PacBio lowered its financial outlook for full-year 2022 due to broader macroeconomic factors like rising inflation, global supply-chain constraints, volatile capital markets and COVID-led lockdown restrictions. Pacific Biosciences of California PACB or PacBio, Avantor AVTR and PerkinElmer PKI were among the companies that led the decline in Medical Devices companies as they fell 11.7%, 8.9% and 6.8%, respectively yesterday.